INGELHEIM, Germany---Thursday 10 September 2020 [ AETOS Wire ]
First-in-class bi-specific antibody BI 905711 activates a pathway in
TRAILR2 and CDH17 co-expressing tumor cells that leads to their
destruction
May result in a more tolerable and selective therapy
for patients affected with gastrointestinal cancers by avoiding liver
toxicity commonly observed in other therapy approaches targeting TRAILR2
Adds a promising candidate to Boehringer Ingelheim’s multipronged
oncology portfolio that combines cancer cell-directed and cancer
immunology approaches to develop novel therapies for previously hard to
treat cancers
(BUSINESS WIRE)-- Boehringer Ingelheim today
announced the advancement of the bi-specific and tetravalent therapeutic
antibody, BI 905711, to its first-in-human clinical trial for patients
with advanced gastrointestinal (GI) cancers. The first-in-class BI
905711 antibody is designed to recognize both the pro-apoptotic tumor
necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2
(TRAILR2) and the tumor cell anchor cadherin 17 (CDH17) to activate the
self-destruction (apoptosis) pathway in co-expressing tumor cells found
mostly in the GI tract. For patients suffering from these types of
cancers, the advancement of the Phase 1 trial marks an important
milestone in the continuing development of more tolerable innovative
therapies to address diseases with high unmet need.
“We are proud
to advance BI 905711 into Phase 1 clinical trials as we continue to
grow our oncology pipeline to transform patients’ lives. This bispecific
platform has the potential to target complex mechanisms that may not be
accessible with traditional antibody formats," said Norbert Kraut,
Ph.D., Head of Global Cancer Research at Boehringer Ingelheim.
Gastrointestinal
cancers are a leading cause of cancer-related deaths throughout the
world. Of gastrointestinal cancers, colorectal cancer, a focus of this
Phase 1 trial, is the third most common cancer with more than 1.8
million cases and the second most deadly cancer with more than 880,000
deaths globally in 2018 (Globocan 2018). To date there have been few
innovative treatment options available for patients diagnosed with GI
malignancies, making chemotherapy, despite its known severe side
effects, the backbone of treatment. A proven targeted therapeutic option
that does not require chemotherapy efficacy support could provide
patients with an alternative, innovative and potentially non-toxic
treatment option.
James Harding, M.D., Principal Investigator,
Department of Early Drug Development and Gastrointestinal Oncology
Service at Memorial Sloan Kettering Cancer Center, New York, USA, said,
“Targeting TRAILR2/CDH17 co-expressing cancer cells has exhibited
preclinical antitumor activity. We look forward to evaluating this
molecule with Boehringer Ingelheim in the ongoing Phase 1 study.”
Patients
with tumors of the gastrointestinal tract are underserved by recent
innovations in cancer therapy and are in critical need of new treatment
options. Boehringer Ingelheim is committed to addressing the unmet need
in these patients’ lives and continues to develop innovative drug
candidates, such as BI 905711, providing potentially powerful and
previously untested approaches to cancer treatment.
Boehringer
Ingelheim Oncology is taking cancer on by leading the science with
cancer cell directed agents, immuno-oncology therapies, and their
combinations to address unmet needs in lung and gastrointestinal
cancers. The company invests significantly in early stage research to
identify unexplored and undrugged pathways of cancer. In 2019,
Boehringer Ingelheim advanced six molecules to first-in-human studies,
including two further first-in-class compounds targeting the
Wnt/β-catenin pathway (BI 905681) and KRAS-driven cancers (BI 1701963),
demonstrating the company’s long term commitment to leading science,
improving clinical practice, and ultimately transforming the lives of
patients – helping them to win the fight against cancer.
Learn more about Boehringer Ingelheim’s innovation in oncology here.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/trailr2-cdh17-antibody-phase1-trial
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005531/en/
Contacts
Media Contacts
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
linda.ruckel@boehringer-ingelheim.com
Permalink
:
https://www.aetoswire.com/news/boehringer-ingelheim-advances-novel-bi-specific-trailr2-cdh17-antibody-to-phase-1-clinical-trial-for-patients-living-with-gastrointestinal-cancers/en
No comments:
Post a Comment